By using the body's own immune system to kill tumor cells, immune cell therapy is anticipated to be a breakthrough strategy to "cure" many types of cancer. Among them, chimeric antigen receptor T-cell immunotherapy (CAR-T) has achieved remarkable results in the treatment of various hematological malignancies. As of 2022, seven CAR-T cell therapy products have been launched globally, including three in China.
The long journey of every CAR-T cell therapy begins with steady steps in performing basic research designed for repeatability. The research process generally includes CAR molecule design, lentiviral packaging, CAR-T cell construction, in vitro and in vivo killing assay, cytotoxicity tests, and more. However, unlike small molecule or antibody drugs, CAR-T is a "live" cell-based drug. In order to build effective and stable CAR-T cells, many factors need to be fully considered, such as rational design of CAR molecular structure, the exploration of T cell transfection conditions, identification of CAR-T cells, and confirmation of purity and potency.
Based on over 16 years of research experience developing cell and animal models for tumor immunology research, Cyagen has built a one-stop service platform for in vivo and in vitro CAR-T cell therapy research. The platform is available to researchers worldwide, which includes scFv sequence screening, CAR molecular design, and full-process services to develop the foundational research for your CAR-T cell therapy. The comprehensive services offered help streamline the efficiency and accuracy of CAR-T/NK research and related fields.
One-stop service platform for CAR-T cell therapy research
Our one-stop platform provides:
1. Viral vector manufacturing
★CAR design
★Lentiviral packaging and optimization
★CAR-T cell construction
2. Tumor Model Construction Platform
★Target cell construction
★C-NKG Severe Immunodeficient Mouse Model
★CDX mouse tumor model
★Humanized model of PBMC/HSC immune system
3. In vitro pharmacodynamic evaluation
★In vitro killing function evaluation of CAR-T cells
★Cytokine detection
★Functional experiments such as cell proliferation/apoptosis/migration/invasion
4. In vivo pharmacodynamic evaluation
★Construction of CDX C-NKG mouse and CDX PBMC/HSC C-NKG mouse models
★Pharmacodynamic evaluation of CAR-T/TCR-T/NK/TIL cells
★Immunohistochemistry (IHC), HE staining, lymphocyte infiltration analysis
How can Cyagen accelerate your CAR-T cell therapy research?
|
Project Type |
Project Technical Difficulties |
The Service Advantages of Cyagen Platform |
|
Target cell construction |
Difficulty in selecting target cell types |
Rich target cell library, with tumor cells/CHO/HEK293 cells overexpressing various targets |
|
The expression level of the target is not high enough |
Experience with 500+ projects for stable transfer plant construction |
|
|
CAR lentivirus packaging |
Lack of experience in CAR molecular structure design |
Rich experience in designing CAR molecules with multiple targets |
|
Low virus titer and difficult purification |
High-quality lentiviral packaging, referenced by multiple publications |
|
|
CAR-T/NK cell construction |
Difficulty in culturing T/NK cells |
16+ years of primary cell culture experience |
|
It is time-consuming to assess the transfection conditions of T/NK cells; the identification of cells after transfection is difficult |
An optimized protocol for fully summarizing the transfection parameters of human/murine immune cells |
|
|
In vitro killing assay |
Difficult to choose evaluation indicators |
Mature in vitro pharmacodynamic experimental platform |
|
Data analysis |
Professional data analyst |
